Dexmedetomidine vs Propofol in High-Risk ERCP Patients
NCT07166614
Summary
ERCP requires deep sedation due to pain and discomfort, but propofol-commonly used with opioids-often causes respiratory and cardiovascular complications, especially in elderly or high-risk patients. Dexmedetomidine offers sedation without respiratory depression but may lower blood pressure and heart rate. Current monitoring often relies only on SpO₂, while capnography and the Integrated Pulmonary Index (IPI) provide earlier detection of respiratory events but are underused in ERCP studies. This study compares dexmedetomidine and propofol in high-risk ERCP patients, focusing on respiratory and hemodynamic effects, propofol consumption, recovery, and discharge times. The hypothesis is that dexmedetomidine will cause fewer adverse respiratory and hemodynamic effects.
Eligibility
Inclusion Criteria: * patients over 18 years of age * ASA physical status III-IV * scheduled for ERCP in the Gastroenterology Endoscopy Unit of our hospital Exclusion Criteria: * pregnant women; * patients with neuropsychiatric disease, * substance abuse, or known allergy to the sedatives used; * patients with baseline heart rate ≤50 bpm; * those who did not provide consent.
Conditions6
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07166614